Modus Therapeutics Holding Past Earnings Performance
Past criteria checks 0/6
Modus Therapeutics Holding has been growing earnings at an average annual rate of 0.9%, while the Biotechs industry saw earnings growing at 13.5% annually.
Key information
0.9%
Earnings growth rate
-7.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -102.6% |
| Net Margin | n/a |
| Next Earnings Update | 23 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Modus Therapeutics Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -15 | 8 | 6 |
| 31 Dec 23 | 0 | -18 | 8 | 8 |
| 30 Sep 23 | 0 | -23 | 7 | 15 |
| 30 Jun 23 | 0 | -23 | 7 | 15 |
| 31 Mar 23 | 0 | -21 | 7 | 14 |
| 31 Dec 22 | 0 | -18 | 7 | 11 |
| 30 Sep 22 | 0 | -21 | 7 | 14 |
| 30 Jun 22 | 0 | -23 | 8 | 15 |
| 31 Mar 22 | 0 | -22 | 8 | 14 |
| 31 Dec 21 | 0 | -21 | 7 | 14 |
| 30 Sep 21 | 0 | -9 | 6 | 4 |
| 30 Jun 21 | 0 | -6 | 4 | 2 |
| 31 Mar 21 | 0 | -5 | 2 | 3 |
| 31 Dec 20 | 0 | -6 | 2 | 4 |
| 31 Dec 19 | 0 | -44 | 7 | 36 |
Quality Earnings: 99Z is currently unprofitable.
Growing Profit Margin: 99Z is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 99Z is unprofitable, but has reduced losses over the past 5 years at a rate of 0.9% per year.
Accelerating Growth: Unable to compare 99Z's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 99Z is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (3%).
Return on Equity
High ROE: 99Z has a negative Return on Equity (-102.64%), as it is currently unprofitable.